IP Library › Granted Patent US 12,653,880
Granted Patent B2
US 12,653,880 · App. 17/748,715 · Granted Jun 16, 2026

SARS-CoV-2 polypeptides

Inventors: Gregory A. Poland (Marco Island, FL); Inna G. Ovsyannikova (Rochester, MN); Richard B. Kennedy (Rochester, MN)
Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
A61K39/215A61K39/39A61P31/14A61K2039/55561A61K2039/575
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,880
App. No.
17/748,715
Granted
Jun 16, 2026
Kind
B2
Abstract

This document provides methods and materials related to selected severe acute respiratory distress coronavirus 2 (SARS-CoV-2) polypeptides. For example, this document provides vaccine compositions that contain one or more selected SARS-CoV-2 polypeptides provided herein and that have the ability to induce or increase immune responses against coronaviruses such as SARS-CoV-2 within a mammal (e.g., a human).

Claims (20)

1 . A substantially pure polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:75.

2 . A composition comprising the substantially pure polypeptide of claim 1 .

3 . The composition of claim 2 , wherein said composition comprises an adjuvant or an immunostimulatory molecule.

4 . The composition of claim 3 , wherein said adjuvant or immunostimulatory molecule is selected from the group consisting of a water in oil emulsion (e.g., Montanide 720, Montanide 51), Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), a CpG oligonucleotide motif, toll-like receptor 4 (TLR4) agonists (e.g., MiT4, EmT4, AIT4, LiT4), aluminum sulfate, aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate, monophosphoryl lipid A, aluminumphosphylate, MF59, AS03, AS04, AS03-like, AS04-like, AS01B-like, GM-CSF, Addavax, AddaS03, retinoic acid-inducible gene I (RIG-I), lipid nanoparticles (e.g., LION), and GLA.

5 . The composition of claim 2 , wherein said polypeptide is presented on a virus-like particle (VLP).

6 . A method for increasing an immune response against a coronavirus in a mammal, wherein said method comprises administering to said mammal a composition comprising a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 75 or nucleic acid encoding said polypeptide.

7 . The method of claim 6 , wherein said coronavirus is a severe acute respiratory distress coronavirus 2 (SARS-COV-2).

8 . The method of claim 6 , wherein said composition comprises an adjuvant or an immunostimulatory molecule.

9 . The method of claim 8 , wherein said adjuvant or immunostimulatory molecule is selected from the group consisting of a water in oil emulsion (e.g., Montanide 720, Montanide 51), Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), a CpG oligonucleotide motif, toll-like receptor 4 (TLR4) agonists (e.g., MiT4, EmT4, AlT4, LiT4), aluminum sulfate, aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate, monophosphoryl lipid A, aluminumphosphylate, MF59, AS03, AS04, AS03-like, AS04-like, AS01B-like, GM-CSF, Addavax, AddaS03, retinoic acid-inducible gene I (RIG-I), lipid nanoparticles (e.g., LION), and GLA.

10 . The method of claim 6 , wherein said polypeptide is presented on a virus-like particle (VLP).

11 . A method for treating a mammal at risk of developing a coronavirus infection, wherein said method comprises administering to said mammal a composition comprising a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:75 or nucleic acid encoding said polypeptide.

12 . The method of claim 11 , wherein said coronavirus infection is COVID-19.

13 . The method of claim 11 , wherein said composition comprises an adjuvant or an immunostimulatory molecule.

14 . The method of claim 13 , wherein said adjuvant or immunostimulatory molecule is selected from the group consisting of a water in oil emulsion (e.g., Montanide 720, Montanide 51), Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), a CpG oligonucleotide motif, toll-like receptor 4 (TLR4) agonists (e.g., MiT4, EmT4, AlT4, LiT4), aluminum sulfate, aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate, monophosphoryl lipid A, aluminumphosphylate, MF59, AS03, AS04, AS03-like, AS04-like, AS01B-like, GM-CSF, Addavax, AddaS03, retinoic acid-inducible gene I (RIG-I), lipid nanoparticles (e.g., LION), and GLA.

15 . The method of claim 11 , wherein said polypeptide is presented on a virus-like particle (VLP).

16 . A method for treating a mammal having a coronavirus infection, wherein said method comprises administering to said mammal a composition comprising a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:75 or nucleic acid encoding said polypeptide.

17 . The method of claim 16 , wherein said coronavirus infection is COVID-19.

18 . The method of claim 16 , wherein said composition comprises an adjuvant or an immunostimulatory molecule.

19 . The method of claim 18 , wherein said adjuvant or immunostimulatory molecule is selected from the group consisting of a water in oil emulsion (e.g., Montanide 720, Montanide 51), Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), a CpG oligonucleotide motif, toll-like receptor 4 (TLR4) agonists (e.g., MiT4, EmT4, AIT4, LiT4), aluminum sulfate, aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate, monophosphoryl lipid A, aluminumphosphylate, MF59, AS03, AS04, AS03-like, AS04-like, AS01B-like, GM-CSF, Addavax, AddaS03, retinoic acid-inducible gene I (RIG-I), lipid nanoparticles (e.g., LION), and GLA.

20 . The method of claim 16 , wherein said polypeptide is presented on a virus-like particle (VLP).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: OVSYANNIKOVA, INNA G; POLAND, GREGORY A; KENNEDY, RICHARD B
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 060891/0988 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: OVSYANNIKOVA, INNA G; POLAND, GREGORY A; KENNEDY, RICHARD B
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 060892/0012 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: POLAND, GREGORY A; OVSYANNIKOVA, INNA G; KENNEDY, RICHARD B
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 060892/0038 →
Continuity (3)
Provisional Application 63341771 · May 13, 2022
Provisional Application 63190964 · May 20, 2021
Related Publication 20220370601A1 · Nov 24, 2022
References Cited (44)
US 10954289B1 · Babb et al. · 2021 [cited by applicant]
US 11191827B1 · Saadi · 2021 [cited by applicant]
US 11510977B2 · Ying · 2022 [cited by examiner]
WO 2013003579A1 · 2013 [cited by applicant]
WO 2015130488A2 · 2015 [cited by applicant]
WO 2015175361A1 · 2015 [cited by applicant]
WO 2018127689A1 · 2018 [cited by applicant]
WO 2019058133A2 · 2019 [cited by applicant]
WO 2019135086A1 · 2019 [cited by applicant]
WO 2019186199A1 · 2019 [cited by applicant]
WO 2019186200A1 · 2019 [cited by applicant]
WO 2019220150A1 · 2019 [cited by applicant]
WO 2021214297A1 · 2021 [cited by applicant]
WO 2021245140A2 · 2021 [cited by applicant]
WO 2022023727A1 · 2022 [cited by applicant]
WO 2022175330A1 · 2022 [cited by applicant]
WO 2022253917A1 · 2022 [cited by applicant]
Albagi et al., “A multiple peptides vaccine against COVID-19 designed from the nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) via the immunoinformatics approach,” [cited by applicant]
Belyakov et al., “Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge,” [cited by applicant]
Crooke et al., “Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome,” [cited by applicant]
Fougeroux et al., “Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity,” [cited by applicant]
Grifoni et al., “A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2,” [cited by applicant]
Herrera, “Immunoinformatics approach in designing SARS-CoV-2 vaccine from experimentally determined SARS-CoV T-cell epitopes,” [cited by applicant]
International Search Report dated Aug. 18, 2022, from International Application PCT/US2022/030068. [cited by applicant]
Jackson et al., “A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses,” [cited by applicant]
Nelde et al., “SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition,” [cited by applicant]
Rammensee et al., “A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer,” [cited by applicant]
Rammensee et al., “Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups,” [cited by applicant]
Ruckwardt et al., “Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial,” [cited by applicant]
Srivastava et al., “Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19)infection, the ongoing pandemic emergency: an in silico approach,” [cited by applicant]
Wadhwa et al., “Harmonization and standardization of immunogenicity assessment of biotherapeutic products,” [cited by applicant]
Ferretti et al., “Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein,” [cited by applicant]
Grifoni et al., “SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19,” [cited by applicant]
Heitmann et al., “A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity,” [cited by applicant]
Khairkhah et al., “Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen,” [cited by applicant]
Meyers et al., “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation,” [cited by applicant]
Nagler et al., “Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics,” [cited by applicant]
Pan et al., “Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs,” [cited by applicant]
Pardieck et al. “A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection,” [cited by applicant]
Tada et al., “Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model,” [cited by applicant]
Weingarten-Gabbay et al., “Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs,” [cited by applicant]
Birtles et al., “Identifying Distinct Structural Features of the SARS-CoV-2 Spike Protein Fusion Domain Essential for Membrane Interaction,” [cited by applicant]
Examination Report dated Oct. 6, 2025, in European Patent Application No. 22 735 677.1, 7 pages. [cited by applicant]
Stoddard et al., “Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs,” [cited by applicant]